decernotinib
Small moleculeexperimental
Decernotinib is an inhibitor of Janus kinase 3 (JAK3) discovered through a process of inhouse screening of a chemical compound library. Decernotinib also had the name VX-509 in development phase. It is an experimental drug with high selectivity for JAK3, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). It has been studied in clinical trials at Vertex Pharmaceuticals, and while it was not approved for clinical use it continues to be used for research. — Wikipedia
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT00789126)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase JAK3INHIBITOR
JAK3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F- Mol. weight
- 392.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDecernotinib ↗
- ChEMBLCHEMBL3039513 ↗
Also known as
- 2-((2-(1h-pyrrolo(2,3-b)pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-n-(2,2,2-trifluoroethyl)butanamide
- adelatinib
- adelatinib
- adelatinib
- decernotinib
- decernotinib
- decernotinib
- decernotinib
- vrt-831509
- vrt-831509
- vx-509
- vx-509
- vx-509
- vx-509
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01886209 | Phase 1 | Jun 1, 2013 | Vertex |
| NCT01830985 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2013 | Vertex |
| NCT01754935 | Phase 2 | Jan 1, 2013 | Vertex |
| NCT01590459 | Phase 2 | Apr 1, 2012 | IQVIA, Vertex |
| NCT01052194 | Phase 2 | Feb 1, 2010 | Vertex |
| NCT00789126 | Phase 1 | Oct 1, 2008 | Vertex |
Showing 6 of 6 trials
Page 1 / 1